News | April 05, 2021
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The vaccine was 85 percent effective in preventing severe disease across all regions.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
Be One is a 100% Ayurvedic health and wellness supplement.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
